IBC's 18th Annual TIDES meeting offers three tracks dedicated for oligonucleotide scientists to learn about the latest strategies and technologies needed to overcome challenges in targeting, drug discovery and oligonucleotide design, process development, regulatory, scale-up manufacturing, investment landscape and more.
Quark's Long History of Oligonucleotide DevelopmentDanny Zurr, Ph.D.
Chairman and Chief Executive Officer Quark Pharmaceuticals Inc. »Read Presentation Abstract
Plus, TIDES offers the largest and most focused exhibit hall for the oligonucleotide industry, where you can access 70+ vendor booths, 40+ posters and evening cocktail networking receptions to help grow your business. You won't want to miss out on this rare opportunity to connect with 800+ like-minded researchers from across the world.
Register with code B16180MOREVIS to receive a $100 savings off the current rate for any main conference option.